Advances in Nanocarriers As Drug Delivery Systems in Chagas Disease

Total Page:16

File Type:pdf, Size:1020Kb

Advances in Nanocarriers As Drug Delivery Systems in Chagas Disease International Journal of Nanomedicine Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Advances in nanocarriers as drug delivery systems in Chagas disease This article was published in the following Dove Press journal: International Journal of Nanomedicine Christian Quijia Quezada1,2 Abstract: Chagas disease is one of the most important public health problems in Latin Clênia S Azevedo1 America due to its high mortality and morbidity levels. There is no effective treatment for Sébastien Charneau3 this disease since drugs are usually toxic with low bioavailability. Serious efforts to achieve Jaime M Santana1 disease control and eventual eradication have been unsuccessful to date, emphasizing the Marlus Chorilli2 need for rapid diagnosis, drug development, and a reliable vaccine. Novel systems for drug and vaccine administration based on nanocarriers represent a promising avenue for Chagas Marcella B Carneiro4 disease treatment. Nanoparticulate systems can reduce toxicity, and increase the efficacy and Izabela Marques Dourado 1 bioavailability of active compounds by prolonging release, and therefore improve the Bastos therapeutic index. Moreover, nanoparticles are able to interact with the host’s immune 1Pathogen-Host Interface Laboratory, system, modulating the immune response to favour the elimination of pathogenic micro- Department of Cell Biology, Institute of organisms. In addition, new advances in diagnostic assays, such as nanobiosensors, are Biology, University of Brasilia, Brasília, Brazil; 2Department of Drugs and beneficial in that they enable precise identification of the pathogen. In this review, we Medicines, São Paulo State University provide an overview of the strategies and nanocarrier-based delivery systems for antichagasic (UNESP), Araraquara, São Paulo, Brazil; agents, such as liposomes, micelles, nanoemulsions, polymeric and non-polymeric nanopar- 3Laboratory of Protein Chemistry and Biochemistry, Department of Cell ticles. We address recent progress, with a particular focus on the advances of nanovaccines Biology, Institute of Biology, University of and nanodiagnostics, exploring new perspectives on Chagas disease treatment. Brasilia, Brasília, Brazil; 4Electron Microscopy Laboratory, Department of Keywords: delivery systems, nanobiosensors, nanodiagnostics, nanoparticle systems, Cell Biology, Institute of Biology, nanovaccine University of Brasilia, Brasília, Brazil Introduction Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic in Latin America, where between five and eight million people are infected. The disease is spreading to non-endemic countries, such as Australia, Canada, Japan, Spain and United States of America (USA).1 It is mainly transmitted by faecal contamination of Reduviidae insects through insect bites or another injury of the skin2 parasite can also be spread by blood transfusion, organ transplantation, congenital contamina- tion, and consumption of contaminated food and drinks.3 The T. cruzi biological cycle is comprised of three fundamental forms: (1) infective trypomastigotes found in mammalian blood and in the hindgut of triatomine bugs as metacyclic forms, (2) epimastigotes, the proliferative form located in the bug’s midgut, and (3) amasti- gotes that multiply by binary fission inside mammalian host cells, causing disrup- Correspondence: Izabela Marques tion and the release of new trypomastigotes into the bloodstream capable of Dourado Bastos invading any nucleated cell to begin a new reproductive cycle.4 Regarding clinical Departamento de Biologia Celular, Universidade de Brasilia, Brasília 70910- symptoms, Chagas disease can manifest both an acute phase which is asymptomatic 900, DF, Brazil in most cases and a chronic phase that is depicted by digestive and/or cardiac Tel +55 613 107 3051 5 Email [email protected] lesions. Treatment is based on the nitroheterocyclic compounds benznidazole and submit your manuscript | www.dovepress.com International Journal of Nanomedicine 2019:14 6407–6424 6407 DovePress © 2019 Quijia Quezada et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing http://doi.org/10.2147/IJN.S206109 the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Quijia Quezada et al Dovepress nifurtimox. However, in long-term therapy, both of the strategies on the treatment of Chagas disease, as well as a aforementioned induce serious side effects and cross-resis- general overview of nanovaccines and nanodiagnostics. tance. To date, research into the production of Chagas disease vaccines has been conducted. The main difficulties General aspects have been finding a protective antigen and generating Physical characteristics of the nanocarriers attenuated parasites that will not trigger pathology in the Some physical characteristics can influence nanocarrier long-term.6 Therefore, in the absence of vaccines, control functions and thus can be strategically explored to control measures for Chagas disease remain limited to diagnosis the Chagas disease, especially against intracellular para- and treatment.5 sites, which are the most difficult forms to eliminate. Nanocarriers has demonstrated important results in These main characteristics are: 1) size of the particles: terms of increasing the efficacy and decreasing the toxicity this feature improves greater bioavailability and circula- of drugs, antigens, and adjuvants currently used against tion time (release, aggregation and transport of the drug), some diseases. The use of nanocarriers against pathogens ranging from 1 to 100 nm or micrometric size (μm).9–11 2) provides a greater ability to overcome biological barriers, Solubility: nanostructures can encapsulate insoluble or maintenance of drug integrity in biological media, with poorly soluble drugs, and the use of them can eliminate higher specificity to target cells and tissues together with the need for toxic organic solvents.12 3) Shape: it can prolonged drug release in comparison to conventional influence interactivity, cellular uptake, retention, biocom- drugs.7 Moreover, nanodiagnostic systems have been patibility, transport and drug loading capacity. The main developed to improve the accuracy of sample preparation shapes are spheres, discs, hemispheres, cylinders, cones, and detection of infectious pathogens by means of a sim- and tubes.10,11 4) Surface area: provides more reactivity as ple, quick, accurate and inexpensive technique.8 the particle size decreases in comparison to larger mole- In this review, we provide an overview of synthetic cules (bulk solids), in addition, they are responsible for the methods, physical characteristics and delivery systems improved water solubility and bioavailability.10 5) Net based on nanocarriers for various antitrypanosomal agents, charge: it can influence the retention in the tissue, the through liposomes, micelles, mesoporous silica nanoparti- circulation half-life and the uptake. In fact, cationic parti- cles, polymeric and non-polymeric nanoparticles (Figure 1). cles can have better uptake in the electrostatic interaction In this context, we highlight new perspectives and innovative with the membrane,13,14 compared to particles with nega- tive charges that have longer circulation half-life.15 The interactions of nanoparticles with their biological environment (molecules, cells, organs) depend on a com- plex interaction between controllable particle properties and largely uncontrollable properties of the surrounding media. Particle size, surface charge, polydispersity index, shape, and surface chemistry are key factors that deter- mine the performance criteria, including the degree of protein adsorption, cell absorption, biodistribution patterns and mechanisms.16 Regarding Chagas disease, these nano- materials must show a high volume of distribution and longer circulation time in the body compared to the avail- able drugs (Nifurtimox or Benznidazole). It has been shown that highly cationic nanoparticles are eliminated from the circulation more rapidly than highly anionic nanoparticles.17 In contrast, neutral nanoparticles, as well as those with a slight negative charge, show significantly longer circulating half-lives, since the negative nature of Figure 1 Nanomaterials used against Chagas disease. Strategies and application of cell membranes allows them to be highly absorbed by nanocarrier-based drug delivery systems, such as liposomes, micelles, mesoporous cells.18–22 Similarly, the size of the nanoparticle, with an silica nanoparticles, polymeric and non-polymeric nanoparticles to optimize the delivery of antitrypanosomal agents. average of less than 200 nm, enables a longer lifetime in 6408 submit your manuscript | www.dovepress.com International Journal of Nanomedicine 2019:14 DovePress Dovepress Quijia Quezada et al the bloodstream, by avoiding interactions with the mono- Gonzalez-Martin et al29 synthesized the same allopur- nuclear phagocyte system and controlling drug delivery.23 inol-loaded polyether cyclic nanoparticles and showed that the pyrazolopyrimidine
Recommended publications
  • Trypanocidal Activity of Ethanolic Leaf Extract of Andrographis Paniculata
    Science World Journal Vol. 15(No 4) 2020 www.scienceworldjournal.org ISSN: 1597-6343 (Online), ISSN: 2756-391X (Print) Published by Faculty of Science, Kaduna State University TRYPANOCIDAL ACTIVITY OF ETHANOLIC LEAF EXTRACT OF ANDROGRAPHIS PANICULATA 1* 2 3 4 Ladan Z., Olanrewaju T. O., Maikaje D.B., and Waziri P. N. Full Length Research Article 1Department of Chemistry, Kaduna State University, Kaduna, Nigeria 2Human African Trypanosomiasis Research Department, Nigerian Institute for Trypanosomiasis Research, Kaduna, Nigeria 3Department of Microbiology, Kaduna State University, Kaduna, Nigeria 4Department of Biochemistry, Kaduna State University, Kaduna, Nigeria *Corresponding Author’s Email Address: [email protected] Phone: 2347030475898 ABSTRACT animal Trypanosomiasis (Achenef and Bekele, 2013; Giordani et Andrographis paniculata used in this study belongs to Acanthacae al., 2016). Various industries are now on the search for sources of family and is commonly known as king of bitters. This study aimed alternative which include synthetic and natural products. Medicinal at evaluating effect of A. paniculata leaf extract on experimental plants remain a major source of alternative medicine and scientific rats infected with Trypanosoma brucei brucei. Cold maceration was investigations have shown that various plants indicate promising used for extraction and the biomass was fractionated in open results for the development of cheaper less toxic drugs for column chromatography. One of the ethanolic fractions obtained treatment and management of trypanosomiasis (Simoben et al., from A. paniculata was evaluated for in vitro and in vivo activities 2018). Andrographis paniculata evaluated in this study belong to using RPMI 1640 cell culture media and experimental wistar rats Acanthacae family of the plant kingdom and commonly known as respectively.
    [Show full text]
  • Of!Transcription!In!The!African! Trypanosome!Trypanosoma*Brucei.!
    ! ! ! ! ! ! Epigenetic!control!of!transcription!in!the!African! Trypanosome!Trypanosoma*brucei.! ! ! ! ! ! by! Louise!Elizabeth!Kerry! ! ! ! ! ! Thesis!submitted!in!partial!fulfillment!of!the!requirements!for!the!degree!of! Doctor!of!Philosophy!(Ph.!D.)!in!Molecular!and!Cellular!Biosciences.! Department!of!Life!Sciences,!Division!of!Cell!and!Molecular!Biology,! Imperial!College!London! ! ! ! ! ! ! Declaration!! ! Declaration!of!originality! I! declare! that! all! of! the! work! presented! in! this! thesis! is! my! own,! and! that! all! else,! information,! data,! results,! figures! and! ideas! from! another! source! or! from! collaborations! have!been!appropriately!referenced!or!acknowledged.! ! ! ! Louise!Elizabeth!Kerry!! November!2017! ! ! Copyright!declaration! The! copyright! of! this! thesis! rests! with! the! author! and! is! made! available! under! a! Creative! Commons!Attribution!NonOCommercial!No!Derivatives!license.!Researches!are!free!to!copy,! distribute!or!transmit!the!thesis!on!the!condition!that!they!attribute!it,!that!they!do!not!use! it!for!commercial!purposes!and!that!they!do!not!alter,!transform!or!build!upon!it.!!For!any! reuse! or! redistribution,! researchers! must! make! clear! to! others! the! license! terms! of! this! work.! ! ! ! ! ! ! 1! Abstract! Abstract! ! Trypanosoma! brucei! relies! on! an! essential! Variant! Surface! Glycoprotein! (VSG)! coat! for! survival!in!the!mammalian!bloodstream.!A!single!VSG!gene!is!transcribed!by!RNA!polymerase!I!(Pol!I)! in! a! strictly! monoallelic! fashion! from! one! of!
    [Show full text]
  • Drugs and Drug Resistance in African Animal Trypanosomosis: a Review
    European Journal of Applied Sciences 5 (3): 84-91, 2013 ISSN 2079-2077 © IDOSI Publications, 2013 DOI: 10.5829/idosi.ejas.2013.5.3.75164 Drugs and Drug Resistance in African Animal Trypanosomosis: A Review Achenef Melaku and Bekele Birasa Department of Veterinary Pharmacy and Biomedical Sciences, Faculty of Veterinary Medicine, University of Gondar, Ethiopia Abstract: Trypanosomosis is the most serious animal health problem in sub-Saharan Africa and prevents the keeping of animals over millions square kilometres of potentially productive land. Trypanocidal drugs belonging to different chemical families and they are used quite intensively in veterinary medicine. Drug for control of animal trypanosomosis relies essentially on three drugs namely homidium salts, diminazene aciturate and isometamidium chloride. About thirty five million doses of trypanocidal drugs are used annually in the treatment of animal trypanosomosis in Africa. Most of these drugs are very old and utilized for a long period of time. Hence, treatment of trypanosomosis is complicated by development of drug resistance. Drug resistance has been reported in 17 countries of Africa. The exact mechanism how trypanosomal parasite develop resistant and the factors responsible for the development of drug resistance are yet to establish. In addition, it is very unlikely that new trypanocidal drugs will be released into the market in the near future. Therefore, it is essential to maintain the efficacy of the currently available drugs through proper utilization. The general features of trypanosomosis, drugs for the treatment and drug resistance in African trypanosomoses are briefly reviewed in this paper and measures to combat drug resistance especially at field level are also suggested.
    [Show full text]
  • Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial Membrane Potential
    Journal of Fungi Review Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial Membrane Potential Nathan P. Wiederhold Fungus Testing Laboratory,Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, San Antonio, TX 78229, USA; [email protected] Abstract: Invasive infections caused by Candida that are resistant to clinically available antifungals are of increasing concern. Increasing rates of fluconazole resistance in non-albicans Candida species have been documented in multiple countries on several continents. This situation has been further exacerbated over the last several years by Candida auris, as isolates of this emerging pathogen that are often resistant to multiple antifungals. T-2307 is an aromatic diamidine currently in development for the treatment of invasive fungal infections. This agent has been shown to selectively cause the collapse of the mitochondrial membrane potential in yeasts when compared to mammalian cells. In vitro activity has been demonstrated against Candida species, including C. albicans, C. glabrata, and C. auris strains, which are resistant to azole and echinocandin antifungals. Activity has also been reported against Cryptococcus species, and this has translated into in vivo efficacy in experimental models of invasive candidiasis and cryptococcosis. However, little is known regarding the clinical efficacy and safety of this agent, as published data from studies involving humans are not currently available. Keywords: T-2307; aromatic diamidine; in vitro susceptibility; mitochondrial membrane; mitochondrial membrane potential; Candida; Cryptococcus Citation: Wiederhold, N.P. Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial 1. Introduction Membrane Potential. J. Fungi 2021, 7, 130.
    [Show full text]
  • WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/337 (2006.01) A61K 31/48 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/395 (2006.01) A61K 31/51 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/4174 (2006.01) A61K 31/549 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/428 (2006.01) A61K 31/663 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/IB20 12/002768 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, 25 October 2012 (25.10.2012) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/552,922 28 October 201 1 (28.
    [Show full text]
  • Human Parasitology
    HUMAN PARASITOLOGY FOURTH EDITION BURTON J. BOGITSH,PHD CLINT E. CARTER,PHD THOMAS N. OELTMANN,PHD AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 225 Wyman Street, Waltham, MA 02451, USA The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK Ó 2013 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the Publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein). Notices Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility. To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.
    [Show full text]
  • Distinct Activation Mechanisms Trigger the Trypanocidal Activity of DNA Damaging Prodrugs
    Distinct activation mechanisms trigger the trypanocidal activity of DNA damaging prodrugs Emma Louise Meredith1#, Ambika Kumar1#, Aya Konno1, Joanna Szular1, Sam Alsford2, Karin Seifert2, David Horn3 and Shane R. Wilkinson1* 1School of Biological & Chemical Sciences, Queen Mary University of London, Mile End Road, London, E1 4NS, UK. 2Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK. 3The Wellcome Trust Centre for Anti-Infectives Research, University of Dundee, Dundee, UK. *Corresponding author: Shane Wilkinson, Mile End Road, London, E1 4NS, UK. Fax: +44 20 882 7732; email: [email protected] #These authors contributed equally to this work. Keywords: DNA repair, interstrand crosslink, prodrug, resistance, RNA interference, gene deletion, type I nitroreductase, cytochrome P450 reductase, SNM1 nuclease Running title: Antiparasitic activities of aziridinyl benzoquinones This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi: 10.1111/mmi.13767 This article is protected by copyright. All rights reserved. SUMMARY Quinone-based compounds have been exploited to treat infectious diseases and cancer, with such chemicals often functioning as inhibitors of key metabolic pathways or as prodrugs. Here, we screened an aziridinyl-1,4-benzoquinone (ABQ) library against the causative agents of trypanosomiasis, and cutaneous leishmaniasis, identifying several potent structures that exhibited EC50 values of <100 nM. However, these compounds also displayed significant toxicity towards mammalian cells indicating that they are not suitable therapies for systemic infections.
    [Show full text]
  • COLIPRIM Liquid
    Your Partners In Success ANTIBIOTICS - VITAMINS - ANTICOCCIDIALS - ANTIFUNGALS - MYCOTOXIN BINDERS ANTIBIOTICS & CHEMOTHERAPEUTICS 3 Welcome Arab Veterinary Industrial Company (AVICO) was founded in 1978 by ambitious youths whose goal was to establish a professional, rapid and competitive veterinary service that Evolved and flourished with the animal health care in Jordan, under that umbrella of values, AVICO Veterinary gradually evolved into a diversified company within its field, a company that knows no boundaries, operating vitally through branches and agents cross the region. Due to the highly regulated industry in which AVICO works, AVICO nowadays has a presence in 21 countries operating in the fields of product development, research, quality control, manufacturing and distribution of veterinary pharmaceuticals, it has a number of products registered worldwide and employs a highly qualified staff. SINCE 1978 - JORDAN 1978 was the year that witnessed the establishment of the first specialized veterinary pharmaceutical company in jordan (AVICO) to rise with the animal health care in jordan, Asia and Africa. AVICO has achieved a distinguished and common confidence in its products due to the excellent solutions it provided to increase the productivity of livestock and poultry in different location and environment. Research Center: The research center R&D, through its divisions, contducted several studies and achieved results that have contributed in the development, not only its own products, but also helped to solve many problems related to livestock and poultry industry in jordan and other countries. The R&D labs, equipped with the best scientific equipment, perform formulation research, stability studies and analytical method developments which are published in defferent scientific journals.
    [Show full text]
  • The Mitochondrion Is a Site of Trypanocidal Action of the Aromatic Diamidine DB75 in Bloodstream Forms of Trypanosoma Bruceiᰔ Charlotte A
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2008, p. 875–882 Vol. 52, No. 3 0066-4804/08/$08.00ϩ0 doi:10.1128/AAC.00642-07 Copyright © 2008, American Society for Microbiology. All Rights Reserved. The Mitochondrion Is a Site of Trypanocidal Action of the Aromatic Diamidine DB75 in Bloodstream Forms of Trypanosoma bruceiᰔ Charlotte A. Lanteri,1 Richard R. Tidwell,1 and Steven R. Meshnick2* Department of Pathology and Laboratory Medicine1 and Departments of Microbiology & Immunology and Epidemiology,2 University of North Carolina, Chapel Hill, North Carolina Received 15 May 2007/Returned for modification 28 July 2007/Accepted 6 December 2007 Human African trypanosomiasis (HAT) is a fatal tropical disease caused by infection with protozoans of the species Trypanosoma brucei gambiense and T. b. rhodesiense. An oral prodrug, DB289, is a promising new therapy undergoing phase III clinical trials for early-stage HAT. DB289 is metabolically converted to the active trypanocidal diamidine DB75 [2,5-bis(4-amidinophenyl)furan]. We previously determined that DB75 inhibits yeast mitochondrial function (C. A. Lanteri, B. L. Trumpower, R. R. Tidwell, and S. R. Meshnick, Antimicrob. Agent Chemother. 48:3968–3974, 2004). The purpose of this study was to investigate if DB75 targets the mitochondrion of T. b. brucei bloodstream forms. DB75 rapidly accumulates within the mitochondria of living trypanosomes, as indicated by the fluorescent colocalization of DB75 with a mitochondrion-specific dye. Fluorescence-activated cell sorting analysis of rhodamine 123-stained living trypanosomes shows that DB75 and other trypanocidal diamidines (pentamidine and diminazene) collapse the mitochondrial membrane potential. DB75 inhibits ATP hydrolysis within T.
    [Show full text]
  • Disulfiram Repurposing in the Combined Chemotherapy of Chagas
    Study Protocol Clinical Trial OPEN Disulfiram repurposing in the combined chemotherapy of Chagas disease A protocol for phase I/II clinical trial ∗ Roberto Magalhães Saraiva, MD, PhDa, , Luciana Fernandes Portela, PhDa, Gabriel Parreiras Estolano da Silveira, MScb, Natalia Lins da Silva Gomes, PhDc, Douglas Pereira Pinto, PhDb, 08/21/2021 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= by http://journals.lww.com/md-cases from Downloaded Aline Campos de Azevedo da Silva, PhDb, Luiz Henrique Conde Sangenis, MD, PhDa, Fernanda Martins Carneiro, MSca, Juliana Almeida-Silva, MScd, Patricia Wink Marinhoe, Downloaded Gilberto Marcelo Sperandio-Silva, PhDa, Rita de Cássia Elias Estrela, PhDa, a a c from Alejandro Marcel Hasslocher-Moreno, MD, PhD , Mauro Felippe Felix Mediano, PhD , Otacilio C. Moreira, PhD , c e f http://journals.lww.com/md-cases Constança Britto, PhD , Sandra Aurora Chavez Perez, PhD , Alessandra Lifsitch Viçosa, PhD , Ana Márcia Suarez-Fontes, PhDd, Marcos André Vannier-Santos, PhDd Abstract Background: Chagas disease (CD) has high morbimortality and the available trypanocidal treatment, including benznidazole (BZ), by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= has limited efficacy in chronic patients. Furthermore, BZ causes adverse effects (AE) that prevent treatment completion in up to 30% of patients. The use of repositioned drugs or drug combination may provide an effective trypanocidal treatment. Disulfiram (DF) may enhance BZ activity and decrease BZ related AE. This study aims to assess the safety of a new combination of drugs for CD therapy, assuming BZ as the drug of choice plus DF as repositioned drug. Methods: This single-centre, open-label, phase I/II clinical trial was designed to evaluate the safety of the combined use of BZ plus DF for CD therapy.
    [Show full text]
  • Trypanocidal and Cytotoxic Effects of 30 Ethiopian Medicinal Plants
    Trypanocidal and Cytotoxic Effects of 30 Ethiopian Medicinal Plants Endalkachew Nibreta,b and Michael Winka,* a Institut für Pharmazie und Molekulare Biotechnologie, Universität Heidelberg, Im Neuenheimer Feld 364, D-69120, Heidelberg, Germany. Fax: +49 6221 544884. E-mail: [email protected] b College of Science, Bahir Dar University, 79 Bahir Dar, Ethiopia * Author for correspondence and reprint requests Z. Naturforsch. 66 c, 541 – 546 (2011); received March 1/September 15, 2011 Trypanocidal and cytotoxic effects of traditionally used medicinal plants of Ethiopia were evaluated. A total of 60 crude plant extracts were prepared from 30 plant species using CH2Cl2 and MeOH. Effect upon cell proliferation by the extracts, for both bloodstream forms of Trypanosoma brucei brucei and human leukaemia HL-60 cells, was assessed using resazurin as vital stain. Of all CH2Cl2 and MeOH extracts evaluated against the trypano- somes, the CH2Cl2 extracts from fi ve plants showed trypanocidal activity with an IC50 value below 20 μg/mL: Dovyalis abyssinica (Flacourtiaceae), IC50 = 1.4 μg/mL; Albizia schimpe- riana (Fabaceae), IC50 = 7.2 μg/mL; Ocimum urticifolium (Lamiaceae), IC50 = 14.0 μg/mL; Acokanthera schimperi (Apocynaceae), IC50 = 16.6 μg/mL; and Chenopodium ambrosioides (Chenopodiaceae), IC50 = 17.1 μg/mL. A pronounced and selective killing of trypanosomes with minimal toxic effect on human cells was exhibited by Dovyalis abyssinica (CH2Cl2 ex- tract, SI = 125.0; MeOH extract, SI = 57.7) followed by Albizia schimperiana (CH2Cl2 extract, SI = 31.3) and Ocimum urticifolium (MeOH extract, SI = 16.0). In conclusion, the screen- ing of 30 Ethiopian medicinal plants identifi ed three species with good antitrypanosomal activities and low toxicity towards human cells.
    [Show full text]
  • Deciphering the Interstrand Crosslink DNA Repair Network Expressed By
    bioRxiv preprint doi: https://doi.org/10.1101/543975; this version posted February 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Deciphering the interstrand crosslink DNA repair network 2 expressed by Trypanosoma brucei 3 4 Ambika Dattani# and Shane Wilkinson* 5 6 School of Biological and Chemical Sciences, Queen Mary University of London, London, E1 7 4NS UK. 8 9 #Current address: School of Life Sciences, Queen's Medical Centre, University of Nottingham, 10 Nottingham, UK. 11 12 13 *Corresponding author. 14 Email: [email protected] 15 16 Short title: Interstrand crosslink repair in trypanosomes. 1 bioRxiv preprint doi: https://doi.org/10.1101/543975; this version posted February 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 17 Abstract 18 Interstrand crosslinks (ICLs) represent a highly toxic form of DNA damage that can block 19 essential biological processes including DNA replication and transcription. To combat their 20 deleterious effects all eukaryotes have developed cell cycle-dependent repair strategies that co- 21 opt various factors from ‘classical’ DNA repair pathways to resolve such lesions. Here, we 22 report that Trypanosoma brucei, the causative agent of African trypanosomiasis, possesses 23 such systems that show some intriguing differences to those mechanisms expressed in other 24 organisms.
    [Show full text]